Latest news with #TransMedics
Globe and Mail
04-07-2025
- Business
- Globe and Mail
Is TransMedics Stock a Buy After Short-Seller Drama?
Explore the exciting world of TransMedics (NASDAQ: TMDX) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of May 28, 2025. The video was published on Jul. 3, 2025. Should you invest $1,000 in TransMedics Group right now? Before you buy stock in TransMedics Group, consider this: Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and TransMedics Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $692,914!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $963,866!* Now, it's worth noting Stock Advisor 's total average return is1,049% — a market-crushing outperformance compared to179%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 30, 2025
Yahoo
30-06-2025
- Business
- Yahoo
2 Stocks That Have Doubled This Year and Are Still Worth Buying
TransMedics Group's innovative approach to storing organs for transplants grants it significant growth fuel. FuboTV's recent merger with a leading media company substantially improved its prospects. 10 stocks we like better than TransMedics Group › Positive, company-specific developments have led to shares of TransMedics Group (NASDAQ: TMDX) and FuboTV (NYSE: FUBO) more than doubling this year, even as the S&P 500 is barely in the green since January. Investing wisdom advises us to buy low, and some might think that after a greater than 100% return in six months, it's too late to get in on these stocks. However, TransMedics Group and FuboTV still have excellent prospects that could lead to better-than-average returns over the long run. TransMedics Group, a medical device specialist that developed an innovative method for storing organs for transplant, entered the year facing challenges. First, the company's guidance disappointed investors. Second, TransMedics was the subject of a short-seller report from Scorpion Capital, which made a series of serious allegations, including claims that TransMedics Group is engaged in organ trafficking. However, the company has performed well this year because of better-than-expected financial results. In the first quarter, TransMedics' revenue increased by 48% year over year to $143.5 million. The company's net earnings per share came in at $0.70, doubling compared to the year-ago period. To top it all off, TransMedics raised its guidance for the full fiscal year 2025. With results like these, even the short-seller report that sank its stock price now looks like a distant memory. The best part is that there is still considerable upside potential for TransMedics Group. The company's organ care system (OCS) technology aims to mimic the physiology of the human body, enabling the storage of organs for longer periods, which results in significantly higher usage rates compared to traditional cold storage methods. It's already hard enough to find available transplants. It's a shame if they go to waste due to poor storage. Thus, TransMedics Group is helping revolutionize the organ donation business thanks to its OCS, and there is plenty of room for growth. The company estimates organ donations will grow at a decent rate through the next few years, at least. Capturing a larger share of the market and improving utilization rates for existing organ donations -- even if there aren't more donors over time -- should lead to stronger financial results for TransMedics Group. That's why the stock remains a buy today, at least for investors willing to stay the course for a while, even after doubling in value already this year. In January, streaming specialist FuboTV announced it was merging with Disney's Hulu+ Live TV. The deal makes FuboTV far more attractive than it was before for several reasons. First, it helps diversify the company's offerings. FuboTV was known for its laser focus on sports streaming, a niche of the market that can be somewhat seasonal. Second, the deal came with the cancellation of the Venu initiative. Disney, Fox, and Warner Bros. Discovery were planning to launch a competing sports-focused streaming platform called Venu, which might have killed FuboTV altogether, considering the company's subscription growth rate had plummeted. Third, FuboTV got a nice infusion of cash as part of the deal. It got $220 million from the former backers of Venu. And that's on top of a $145 million term loan from Disney. Last but not least, Disney is now FuboTV's majority shareholder. The backing of a longtime successful media giant with equally successful ventures in the streaming niche will be of massive help to FuboTV. Yes, the stock has already skyrocketed this year, but considering the long-term opportunity in streaming, there should still be plenty of upside for FuboTV. Streaming accounted for 44.8% of television viewing time in May in the U.S., surpassing the combined share of broadcast and cable for the first time. Even so, that's in the U.S., one of the more penetrated markets. And even here, streaming likely hasn't peaked. That points to a massive whitespace worldwide. FuboTV will have to deal with stiff competition, but the company's new standing after the merger with Hulu+ Live TV -- and the backing of Disney -- should work wonders over the long run. That's why the stock is still a buy. Before you buy stock in TransMedics Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and TransMedics Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends TransMedics Group, Walt Disney, Warner Bros. Discovery, and fuboTV. The Motley Fool has a disclosure policy. 2 Stocks That Have Doubled This Year and Are Still Worth Buying was originally published by The Motley Fool
Globe and Mail
30-06-2025
- Business
- Globe and Mail
2 Stocks That Have Doubled This Year and Are Still Worth Buying
Positive, company-specific developments have led to shares of TransMedics Group (NASDAQ: TMDX) and FuboTV (NYSE: FUBO) more than doubling this year, even as the S&P 500 is barely in the green since January. Investing wisdom advises us to buy low, and some might think that after a greater than 100% return in six months, it's too late to get in on these stocks. However, TransMedics Group and FuboTV still have excellent prospects that could lead to better-than-average returns over the long run. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » 1. TransMedics Group TransMedics Group, a medical device specialist that developed an innovative method for storing organs for transplant, entered the year facing challenges. First, the company's guidance disappointed investors. Second, TransMedics was the subject of a short-seller report from Scorpion Capital, which made a series of serious allegations, including claims that TransMedics Group is engaged in organ trafficking. However, the company has performed well this year because of better-than-expected financial results. In the first quarter, TransMedics' revenue increased by 48% year over year to $143.5 million. The company's net earnings per share came in at $0.70, doubling compared to the year-ago period. To top it all off, TransMedics raised its guidance for the full fiscal year 2025. With results like these, even the short-seller report that sank its stock price now looks like a distant memory. The best part is that there is still considerable upside potential for TransMedics Group. The company's organ care system (OCS) technology aims to mimic the physiology of the human body, enabling the storage of organs for longer periods, which results in significantly higher usage rates compared to traditional cold storage methods. It's already hard enough to find available transplants. It's a shame if they go to waste due to poor storage. Thus, TransMedics Group is helping revolutionize the organ donation business thanks to its OCS, and there is plenty of room for growth. The company estimates organ donations will grow at a decent rate through the next few years, at least. Capturing a larger share of the market and improving utilization rates for existing organ donations -- even if there aren't more donors over time -- should lead to stronger financial results for TransMedics Group. That's why the stock remains a buy today, at least for investors willing to stay the course for a while, even after doubling in value already this year. 2. FuboTV In January, streaming specialist FuboTV announced it was merging with Disney 's Hulu+ Live TV. The deal makes FuboTV far more attractive than it was before for several reasons. First, it helps diversify the company's offerings. FuboTV was known for its laser focus on sports streaming, a niche of the market that can be somewhat seasonal. Second, the deal came with the cancellation of the Venu initiative. Disney, Fox, and Warner Bros. Discovery were planning to launch a competing sports-focused streaming platform called Venu, which might have killed FuboTV altogether, considering the company's subscription growth rate had plummeted. Third, FuboTV got a nice infusion of cash as part of the deal. It got $220 million from the former backers of Venu. And that's on top of a $145 million term loan from Disney. Last but not least, Disney is now FuboTV's majority shareholder. The backing of a longtime successful media giant with equally successful ventures in the streaming niche will be of massive help to FuboTV. Yes, the stock has already skyrocketed this year, but considering the long-term opportunity in streaming, there should still be plenty of upside for FuboTV. Streaming accounted for 44.8% of television viewing time in May in the U.S., surpassing the combined share of broadcast and cable for the first time. Even so, that's in the U.S., one of the more penetrated markets. And even here, streaming likely hasn't peaked. That points to a massive whitespace worldwide. FuboTV will have to deal with stiff competition, but the company's new standing after the merger with Hulu+ Live TV -- and the backing of Disney -- should work wonders over the long run. That's why the stock is still a buy. Should you invest $1,000 in TransMedics Group right now? Before you buy stock in TransMedics Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and TransMedics Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor 's total average return is1,062% — a market-crushing outperformance compared to177%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 23, 2025
Yahoo
26-06-2025
- Business
- Yahoo
Oppenheimer Raises TransMedics (TMDX) PT to $150 Following Key OrganOx Metra Label Update
TransMedics Group Inc. (NASDAQ:TMDX) is one of the best mid cap growth stocks to invest in now. On June 17, Oppenheimer increased the price target for TransMedics to $150 from $130, while maintaining an Outperform rating on the shares. This adjustment came after the OrganOx Metra device had its air transport warning removed from its label on June 2. The OrganOx Metra device is a competitor in the organ preservation market. Despite mixed outcomes from field checks on the Metra device, OrganOx continues to receive positive feedback from the Organ Procurement Organization community. Oppenheimer expects that the OrganOx Metra device will likely gain market share in DCD/Donation after Circulatory Death liver transplants. This is attributed not necessarily to superior outcomes compared to TransMedics' technology, but rather to a perceived strained relationship between TransMedics and the OPOs. A surgeon in a modern operating theatre performing a transplant surgery with medical technology. In Q1 2025, TransMedics achieved a record total revenue of $143.5 million, which showed a 48% year-over-year growth compared to $96.9 million in Q1 2024. Transplant services revenue specifically saw a 56% increase due to higher utilization of their OCS NOP/Organ Care System National Organ Preservation platform. TransMedics also raised its full-year 2025 revenue guidance to a range between $565 and $585 million, which represents a 30% growth at the midpoint. TransMedics Group Inc. (NASDAQ:TMDX) is a commercial-stage medical technology company that transforms organ transplant therapy for end-stage organ failure patients internationally. While we acknowledge the potential of TMDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
18-06-2025
- Business
- Yahoo
TransMedics (TMDX) Continues to Scale Innovation in Organ Transplant Care
TransMedics Group Inc. (NASDAQ:TMDX) is one of the 10 best growth stocks to buy according to billionaires. The stock has had a tremendous year so far, with share price gains of 129%, leading other stocks in this list by a considerable margin, as none of the other stocks here have even reached 100%. In 2024, the company's revenue surged a robust 83%, and the street expects it to post a solid 31% growth in FY 2025. The company is also likely to experience significantly improved profitability, as consensus EPS forecasts a 77% growth this year and a 38% growth next year. A doctor performing a living donor kidney transplant in a hospital operating room, emphasizing the importance of medical advancements. On June 9, Canaccord Genuity analyst William Plovanic reaffirmed a Buy rating on TransMedics Group Inc. (NASDAQ:TMDX) with an unchanged price target of $129. This reaffirmation follows the company's June 9 presentation at the Goldman Sachs Global Healthcare Conference, where the company reaffirmed the strategy behind its industry-leading position in organ transplantation. Its execution continues to support a positive outlook, with management sharing tangible progress toward its long-term targets. At the centre of the story is the National OCS Program (NOP), which now drives nearly all company revenue, enabling TransMedics to offer a full-service, end-to-end transplant logistics and technology solution. This model has not only boosted transplant volumes but also established a critical advantage that competitors have yet to replicate. The company is targeting $1.2 billion in revenue and a 30% operating margin by 2028, driven by the expanded adoption of its Organ Care System and the upcoming next-generation platforms. Notably, its leadership in the DCD (donation after circulatory death) heart category, which now makes up about half of all U.S. heart donors, reflects its role in expanding the donor pool. TransMedics Group Inc. (NASDAQ:TMDX) is well-positioned to introduce new platforms for heart, lung, and kidney care in the coming years, including a Gen 3 system designed for greater portability and scalability. With strong clinical data and operational depth, the company appears well-positioned to hit its 10,000 annual transplants milestone by 2028 and continue growing from there. Management expects its kidney platform to launch by 2027 and aims to achieve 20,000 to 30,000 transplants over the next three to five years. TransMedics Group Inc. (NASDAQ:TMDX) is a commercial-stage medical technology company offering organ transplant therapy for patients with end-stage organ failure across multiple disease states. While we acknowledge the potential of TMDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
